Bexarotene

Non-Small Cell Lung Carcinoma

Dartmouth-Hitchcock Medical CenterSmall moleculePhase 3Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 65/ 100

Competitive context

1128 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
Veliparib AbbVie	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB
Icotinib The First Affiliated Hospital of Guangzhou Medical University	Phase 4	BBB

View all 50 →

Same molecule, other indications

Bexarotene is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaActive

BBB

Indicative · Phase 4

74 / 100

primary cutaneous anaplastic large cell lymphomaDormant

BB

Indicative · Phase 3

65 / 100

mycosis fungoidesActive

B

Indicative · Phase 3

63 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.